Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back Reimbursement To 340B Providers

 
• By Cathy Kelly

HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.

Montreal, CA - 8 October 2015: Gilead truvada pills in a hand. Contributor: Marc Bruxelle / Alamy Stock Photo Image ID: 2BDRDBE
Another Case Of Providers Relying On A 340B Spread For Operating Revenue? • Source: Alamy

More from Pricing Debate

More from Market Access